NCT06617429Phase 3Terminated

Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)

Study sponsor: Ultragenyx Pharmaceutical Inc · RARE

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-07-10Actual
Enrollment · participants129Actual
Source updated2026-11-03Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Jul 2026. After: 10 Jul 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview